By: Adam Feuerstein | 06/02/14 - 03:20 PM EDT
It's me again, still reporting from the American Society of Clinical Oncology (ASCO) annual meeting. We just got our first look at the clinical activity of Incyte's (INCY) immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with Bristol-Myers Squibb's (BMY) Yervoy in melanoma patients. The Wall Street scrum around the Incyte poster was insane.
$INCY IDO poster scrum. #ASCO14 pic.twitter.com/yAk04mYGJ5 Adam Feuerstein (@adamfeuerstein) June 2, 2014Oh yeah, you're probably interesting in hearing about the data. Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response rate of 50%. A third patient reported stable disease so the disease control rate was 75%. The Incyte press release and poster can be found here.
Seeing a complete response is always a good sign, so while the number of patients treated in the 50 mg cohort is small, there's enough clinical activity here to justify running new combination studies of '360 and the PD-1 inhibitors from Bristol, Merck (MRK) and others.
We last saw data on '360 at the 25 mg dose when the ASCO abstracts were released in mid May.
Incyte shares rebounded big time when the '360 data were announced this afternoon.
INCY Price data by YCharts
08/26/14 - 07:00 AM EDT
08/25/14 - 08:48 AM EDT
08/21/14 - 10:23 AM EDT
08/14/14 - 10:20 AM EDT
08/13/14 - 12:04 PM EDT
08/29/14 - 12:03 PM EDT
08/28/14 - 12:00 PM EDT
08/27/14 - 11:32 AM EDT
08/26/14 - 14:30 PM EDT
08/26/14 - 11:34 AM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.